William Blair analyst Sami Corwin has maintained their bullish stance on ACLX stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sami Corwin has given his Buy rating due to a combination of factors including the promising clinical data from Arcellx’s Phase II iMMagine-1 study of anito-cel for relapsed/refractory multiple myeloma. The study’s results, which were reiterated at the European Hematology Association conference, demonstrated significant efficacy with an 18-month progression-free survival rate of 66% and an overall survival rate of 90%. These findings suggest a competitive advantage for anito-cel in the treatment landscape.
Additionally, Arcellx’s progress towards commercialization is a key factor in the Buy rating. The company has completed its pre-BLA meeting with the FDA and is on track for a potential commercial launch in the second half of 2026. The anticipated submission of the BLA within the next three months further supports the positive outlook. Furthermore, comparative analyses with existing treatments, such as Carvykti, highlight anito-cel’s potential efficacy, enhancing confidence in its market potential.
Corwin covers the Healthcare sector, focusing on stocks such as Cabaletta Bio, BioMarin Pharmaceutical, and Ultragenyx Pharmaceutical. According to TipRanks, Corwin has an average return of 25.7% and a 54.82% success rate on recommended stocks.
In another report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $130.00 price target.